SpringerLink
Log in

Comparative study of weekly and three-weekly neoadjuvant carboplatin in triple-negative breast cancer: retrospective analysis in real-world settings

  • BRIEF RESEARCH ARTICLE
  • Published:
Clinical and Translational Oncology Aims and scope Submit manuscript

Abstract

Purpose

Tri-weekly carboplatin is an established neoadjuvant treatment for triple-negative breast cancer, enhancing pathological complete response (pCR) and overall survival. This study explores if weekly carboplatin provides lower toxicity and comparable pCR rates.

Methods/patients

A retrospective multicenter study (January 2021 to March 2023) compares outcomes of weekly and tri-weekly carboplatin.

Results

Among 104 participants, 60% received weekly and 40% tri-weekly treatments. Weekly administration had fewer discontinuations (56.5 vs. 70.7%, p = 0.154). Both schedules exhibited similar overall toxicity (p = 0.087), with slightly higher grade 3–4 toxicity in the tri-weekly group (56.1 vs. 48.4%, p = 0.126). Hematological toxicity was comparable, but the weekly group experienced more diarrhea (p = 0.432) and asthenia (p = 0.012). Weekly treatment correlated with more frequent breast-conserving surgeries (p = 0.004). pCR rates were 50% with weekly and 61% with tri-weekly regimens (p = 0.186).

Conclusions

Weekly carboplatin exhibited comparable toxicity, a trend toward fewer interruptions, and similar pCR rates. Prospective studies are essential for validating these findings.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Data availability

Data are available from the first author on request.

References

  1. Morris GJ, Naidu S, Topham AK, Guiles F, Xu Y, McCue P, et al. Differences in breast carcinoma characteristics in newly diagnosed African-American and Caucasian patients: a single-institution compilation compared with the National Cancer Institute’s Surveillance, Epidemiology, and End Results database. Cancer [Internet]. 2007;110(4):876–84. https://doi.org/10.1002/cncr.22836.

    Article  PubMed  Google Scholar 

  2. Spring LM, Arfe A. Pathological complete response (pCR) after neoadjuvant chemotherapy and impact on breast cancer recurrence and survival, stratified by breast cancer subtypes and adjuvant chemotherapy usage: Patient-level meta-analyses of over 27,000 patients. In: Proceedings from the 2018 San Antonio Breast Cancer Symposium (SABCS) Dec. 2018. p. 4–8.

  3. Shepherd JH, Ballman K, Polley M-YC, Campbell JD, Fan C, Selitsky S, et al. CALGB 40603 (alliance): Long-term outcomes and genomic correlates of response and survival after neoadjuvant chemotherapy with or without carboplatin and bevacizumab in triple negative breast cancer. J Clin Oncol [Internet]. 2022;40(12):1323–34. https://doi.org/10.1200/jco.21.01506.

  4. Loibl S, Weber KE, Timms KM, Elkin EP, Hahnen E, Fasching PA, et al. Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response—final results from GeparSixto. Ann Oncol [Internet]. 2018;29(12):2341–7. https://doi.org/10.1093/annonc/mdy460.

    Article  CAS  PubMed  Google Scholar 

  5. Sharma P, Kimler BF, O’Dea A, Nye L, Wang YY, Yoder R, et al. Randomized phase II trial of anthracycline-free and anthracycline-containing neoadjuvant carboplatin chemotherapy regimens in stage I-III triple-negative breast cancer (NeoSTOP). Clin Cancer Res [Internet]. 2021;27(4):975–82. https://doi.org/10.1158/10780432.ccr-20-3646.

    Article  CAS  PubMed  Google Scholar 

  6. Oualla K, El-Zawahry HM, Arun B, Reuben JM, Woodward WA, Gamal El-Din H, et al. Novel therapeutic strategies in the treatment of triple-negative breast cancer. Ther Adv Med Oncol [Internet]. 2017;9(7):493–511. https://doi.org/10.1177/1758834017711380.

    Article  CAS  PubMed  Google Scholar 

  7. Wang L-Y, **e H, Zhou H, Yao W-X, Zhao X, Wang Y. Efficacy of carboplatin-based preoperative chemotherapy for triple-negative breast cancer: a meta-analysis of randomized controlled trials. Saudi Med J [Internet]. 2017;38(1):18–23.

    Article  CAS  PubMed  Google Scholar 

  8. Pathak N, Sharma A, Elavarasi A, Sankar J, Deo SVS, Sharma DN, et al. Moment of truth-adding carboplatin to neoadjuvant/adjuvant chemotherapy in triple negative breast cancer improves overall survival: an individual participant data and trial-level meta analysis. Breast [Internet]. 2022;64:7–18. https://doi.org/10.1016/j.breast.2022.04.006.

    Article  PubMed  Google Scholar 

  9. Lee E, McKean-Cowdin R, Ma H, Spicer DV, Van Den Berg D, Bernstein L, et al. Characteristics of triple-negative breast cancer in patients with a BRCA1 mutation: results from a population-based study of young women. J Clin Oncol [Internet]. 2011;29(33):4373–80. https://doi.org/10.1200/JCO.2010.33.6446.

    Article  PubMed  Google Scholar 

  10. Sikov WM, Berry DA, Perou CM, Singh B, Cirrincione CT, Tolaney SM, et al. Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance). J Clin Oncol [Internet]. 2015;33(1):13–21. https://doi.org/10.1200/jco.2014.57.0572.

    Article  CAS  PubMed  Google Scholar 

  11. Poggio F, Bruzzone M, Ceppi M, Pondé NF, La Valle G, Del Mastro L, et al. Platinum-based neoadjuvant chemotherapy. Ann Oncol (Internet). 2018;29(7):1497–508. https://doi.org/10.1093/annonc/mdy127.

    Article  CAS  Google Scholar 

  12. Landry KK, Lyon JL, Victoria KE, Changizzadeh PN, Cole BF, Pulluri B, et al. Weekly vs every 3-week carboplatin with weekly paclitaxel in neoadjuvant chemotherapy for triple-negative breast cancer: a retrospective analysis. Breast cancer (Dove Med Press) (Internet): 2020;14:63–70. https://doi.org/10.2147/bctt.s342635.

  13. Yu K-D, Ye F-G, He M, Fan L, Ma D, Mo M, et al. Effect of adjuvant paclitaxel and carboplatin on survival in women with triple-negative breast cancer: A phase 3 randomized clinical trial. JAMA Oncol [Internet]. 2020;6(9):1390. https://doi.org/10.1001/jamaoncol.2020.2965.

    Article  PubMed  Google Scholar 

Download references

Author information

Author notes

  1. Ana Isabel Martin-Quesada

    Present address: Immuno Oncology Unit, Centre Hospitalier Universitaire, Rue de Bugnon 46, 1005, Lausanne, Switzerland

Authors and Affiliations

  1. Medical Oncologist, University Hospital Nuestra Señora de Candelaria, Ctra. Gral. del Rosario, 145, 38010, Santa Cruz de Tenerife, Spain

    Ana Isabel Martin-Quesada, Natalia Rodríguez-Pérez, Alicia Herrero-Márquez & Isaac Núñez-Hernández

  2. Medical Oncologist, Insular Materno-Infantil University Hospital, Avenida Marítima del Sur, S/N, 35016, Las Palmas de Gran Canaria, Las Palmas, Spain

    Elisenda Llabres-Valentí & Cristina María Montesdeoca-Godoy

  3. Medical Oncologist, University Hospital of the Canary Islands, Carretera Ofra S/N, 38320, La Laguna, Santa Cruz de Tenerife, Spain

    Carla Martín-Abreu, Cristina Alemán-Sánchez & Josefina Cruz-Jurado

  4. Medical Oncologist, Doctor Negrín University Hospital, C. Pl. Barranco de La Ballena, S/N, 35010, Las Palmas de Gran Canaria, Las Palmas, Spain

    María Hernández-Sosa & Melody Marrero-García

  5. Medical Oncologist, Virgen de La Peña General Hospital, Carretera del Aeropuerto, Km 1, 35600, Puerto del Rosario, Las Palmas, Spain

    Cristina Victoria DelPino-Hernández & Samuel José Hernández-Sarmiento

  6. Medical Oncologist, University Hospital de La Palma, LP-3, 28, 38713, Breña Alta, Santa Cruz de Tenerife, Spain

    Alejandra Rodríguez-Capote

  7. Department of Clinical Epidemiology and Biostatistics, Research Unit, University Hospital Nuestra Señora de Candelaria Tenerife and Primary Care Management, Santa Cruz de Tenerife, Spain

    Lina Pérez-Méndez

  8. Networked Biomedical Research Centre (CIBER) of Respiratory Diseases, Ctra. Gral. del Rosario, Carlos III Health Institute, 145, 38010, Santa Cruz de Tenerife, Spain

    Lina Pérez-Méndez

Authors
  1. Ana Isabel Martin-Quesada
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Elisenda Llabres-Valentí
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Cristina María Montesdeoca-Godoy
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Carla Martín-Abreu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Cristina Alemán-Sánchez
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Natalia Rodríguez-Pérez
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Alicia Herrero-Márquez
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Josefina Cruz-Jurado
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. María Hernández-Sosa
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Melody Marrero-García
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Cristina Victoria DelPino-Hernández
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Samuel José Hernández-Sarmiento
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Alejandra Rodríguez-Capote
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Lina Pérez-Méndez
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Isaac Núñez-Hernández
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ana Isabel Martin-Quesada.

Ethics declarations

Ethical approval (Research involving human participants and/or animals)

The study was approved by the hospital’s ethics committee.

Informed consent

Exention of Informed consent accepted by the Ethical commitee.

Conflict of interest

Josefina Cruz-Jurado: Fee: Roche, Pfyzer, Novartis, Lilly, Glaxo, Eisai, Pierre Fabre, Pharmamar, Daichii, Astra Zaneca, Glaxo, seagen, Gilead Advisory: Roche, Pfyzer, Novartis, Lilly, Glaxo, Eisai, Pierre Fabre, Pharmamar, Daichii, Astra Zaneca, Glaxo ,seagen, Gilead. The other authors declare no conflicts of interest in relation to the current article.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Martin-Quesada, A.I., Llabres-Valentí, E., Montesdeoca-Godoy, C.M. et al. Comparative study of weekly and three-weekly neoadjuvant carboplatin in triple-negative breast cancer: retrospective analysis in real-world settings. Clin Transl Oncol (2024). https://doi.org/10.1007/s12094-024-03430-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s12094-024-03430-7

Keywords

Search

Navigation